Evidence map›Paper›PMID 34885950›Full record

ReviewMolecules (Basel, Switzerland)2021

Berberine as a Potential Anticancer Agent: A Comprehensive Review.

Abdur Rauf, Tareq Abu-Izneid, Anees Ahmed Khalil, Muhammad Imran, Zafar Ali Shah, Talha Bin Emran, Saikat Mitra, Zidan Khan, Fahad A Alhumaydhi, Abdullah S M Aljohani and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 3 pooled it
29.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 3 syntheses or guidelines pooled it, 272 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Retrospection ofMini reviews in medicinal chemistry · 2026
    Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 6 countries.

Abdur RaufDepartment of Chemistry, University of Swabi, Anbar 23561, Pakistan.ORCID 0000-0003-2429-5491
Tareq Abu-IzneidPharmaceutical Sciences Program, College of Pharmacy, Al Ain University, Al Ain 64141, United Arab Emirates.
Anees Ahmed KhalilUniversity Institute of Diet and Nutritional Sciences, Faculty of Allied Health Sciences, The University of Lahore, Lahore 54000, Pakistan.ORCID 0000-0003-3662-0933
Muhammad ImranUniversity Institute of Diet and Nutritional Sciences, Faculty of Allied Health Sciences, The University of Lahore, Lahore 54000, Pakistan.
Zafar Ali ShahDepartment of Chemistry, University of Swabi, Anbar 23561, Pakistan.
Talha Bin EmranDepartment of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.ORCID 0000-0003-3188-2272
Saikat MitraDepartment of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh.
Zidan KhanDepartment of Pharmacy, International Islamic University Chittagong, Chittagong 4318, Bangladesh.
Fahad A AlhumaydhiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 52571, Saudi Arabia.ORCID 0000-0002-0151-8309
Abdullah S M AljohaniDepartment of Veterinary Medicine, College of Agriculture and Veterinary Medicine, Qassim University, Buraydah 52571, Saudi Arabia.
Ishaq KhanInstitute of Basic Medical Sciences, Khyber Medical University, Peshawar 25100, Pakistan.
Md Mominur RahmanDepartment of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh.ORCID 0000-0003-2357-283X
Philippe JeandetUniversity of Reims Champagne-Ardenne, Research Unit, Induced Resistance and Plant Bioprotection, EA 4707, USC INRAe 1488, SFR Condorcet FR CNRS 3417, Faculty of Sciences, P.O. Box 1039, CEDEX 2, 51687 Reims, France.ORCID 0000-0003-3023-4871
Tanweer Aslam GondalSchool of Exercise and Nutrition, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia.ORCID 0000-0002-3814-5227
Qassim University · SAUniversity of Lahore · PKUniversity of Swabi · PKAl Ain University · AEBGC Trust University Bangladesh · BDCentre National de la Recherche Scientifique · FRDaffodil International University · BDDeakin University · AUInternational Islamic University Chittagong · BDKhyber Medical University · PKUniversity of Dhaka · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Berberine (BBR), a potential bioactive agent, has remarkable health benefits. A substantial amount of research has been conducted to date to establish the anticancer potential of BBR. The present review consolidates salient information concerning the promising anticancer activity of this compound. The therapeutic efficacy of BBR has been reported in several studies regarding colon, breast, pancreatic, liver, oral, bone, cutaneous, prostate, intestine, and thyroid cancers. BBR prevents cancer cell proliferation by inducing apoptosis and controlling the cell cycle as well as autophagy. BBR also hinders tumor cell invasion and metastasis by down-regulating metastasis-related proteins. Moreover, BBR is also beneficial in the early stages of cancer development by lowering epithelial-mesenchymal transition protein expression. Despite its significance as a potentially promising drug candidate, there are currently no pure berberine preparations approved to treat specific ailments. Hence, this review highlights our current comprehensive knowledge of sources, extraction methods, pharmacokinetic, and pharmacodynamic profiles of berberine, as well as the proposed mechanisms of action associated with its anticancer potential. The information presented here will help provide a baseline for researchers, scientists, and drug developers regarding the use of berberine as a promising candidate in treating different types of cancers.

Indexed as

AnimalsAntineoplastic AgentsApoptosisAutophagyBerberineCell CycleCell ProliferationHumansNeoplasmsAntineoplastic AgentsBerberinealkaloidsberberinecancercancer preventive agentspharmacokinetic study

Identifiers

PMID34885950
PMCPMC8658774
OpenAlexW4200394407

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.